Last $0.93 USD
Change Today +0.0362 / 4.03%
Volume 419.8K
STEM On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Open
$0.90
Previous Close
$0.90
Day High
$0.94
Day Low
$0.89
52 Week High
07/3/14 - $2.43
52 Week Low
12/17/14 - $0.84
Market Cap
64.2M
Average Volume 10 Days
928.4K
EPS TTM
$-0.53
Shares Outstanding
68.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cell-based research and drug discovery and development. It develops HuCNS-SC cells that completed Phase I clinical trial in pelizaeus-merzbacher disease, a fatal myelination disorder in brain; completed a Phase I clinical trial in infantile and late infantile neuronal ceroid lipofuscinosis, which is a neurodegenerative disorder of the brain; and conducting preclinical studies in alzheimer’s disease. The company is also developing HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of chronic spinal cord injury, as well as for dry age-related macular degeneration. In addition, it is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company markets a range of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. Its proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. The company serves researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

58 Employees
Last Reported Date: 03/13/14
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $835.8K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
General Counsel and Secretary
Total Annual Compensation: $377.0K
Compensation as of Fiscal Year 2013.

stemcells inc (STEM) Key Developments

StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury Pathway Study to Assess Potential of Human Neural Stem Cells to Restore Motor Function

StemCells Inc. announced that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI). The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis. The Pathway Study is the first clinical trial designed to evaluate both the safety and efficacy of transplanting human neural stem cells into patients with cervical spinal cord injury. Traumatic injuries to the cervical (neck) region of the spinal cord, also known as tetraplegia or quadriplegia, impair sensation and motor function of the hands, arms, legs, and trunk. The trial will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders. The trial will follow the participants for one year and will enroll up to 52 subjects. The company completed enrollment and dosing in its open-label Phase I/II study in thoracic spinal cord injury in May 2014 and has reported interim results on all 12 subjects. Post-transplant gains in sensory function below the level of injury were demonstrated in half of the subjects. Two subjects converted from a complete injury (AIS A) to an incomplete injury (AIS B). The interim results also continue to confirm the favorable safety profile of the cells and the surgical procedure.

StemCells, Inc. Receives CIRM Notice of Termination to Terminate Loan Award

On December 12, 2014, StemCells Inc. received a CIRM Notice of loan award termination to terminate the company’s loan award, DR2A-05416. In September 2012, CIRM awarded the company up to approximately $19 million to fund the company’s research of restoration of memory in Alzheimers disease using neural stem cell therapy. The decision to terminate the loan award was due to the occurrence of a no go milestone in accordance with Section 8.1(f) of the loan agreement. The final amount of the loan award will be determined upon submission of the final financial report and the loan balance will be forgiven.

StemCells Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

StemCells Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of USD 269,000 compared to USD 325,000 a year ago. Loss from operations was USD 6,517,000 compared to USD 6,656,000 a year ago. Net loss was USD 2,757,000 compared to USD 7,192,000 a year ago. Basic and diluted loss per share was USD 0.04 compared to USD 0.28 a year ago. The decrease of 17% in revenue from 2013 to 2014 was primarily due to lower revenue from SC Proven product sales in the third quarter of 2014. For the nine months, the company reported total revenue of USD 851,000 compared to USD 891,000 a year ago. Loss from operations was USD 21,521,000 compared to USD 19,134,000 a year ago. Net loss was USD 22,493,000 compared to USD 19,476,000 a year ago. Basic and diluted loss per share was USD 0.38 compared to USD 0.49 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.93 USD +0.0362

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.30 USD 0.00
Biorestorative Therapies Inc $0.50 USD +0.01
Cytori Therapeutics Inc $0.50 USD +0.0201
Nuo Therapeutics Inc $0.34 USD +0.0101
Vericel Corp $2.99 USD +0.12
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 53.4x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit www.stemcellsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.